| abstract |
The present invention provides the use of an orally active, long acting, CNSpenetrant NK-1 receptor antagonist for the manufacture of a medicament adapted for oral administration for the treatment or prevention of bipolar disorder without concomitant therapy with other antidepressant or anti-anxiety agents, methods of treatment using such an NK-1 receptor antagonist and pharmaceutical compositions comprising the same. |